Results 11 to 20 of about 2,682 (215)
SGLT2 Inhibitors: Physiology and Pharmacology [PDF]
Kidney360, 2021 SGLTs are sodium glucose transporters found on the luminal membrane of the proximal tubule, where they reabsorb some 180 g (1 mol) of glucose from the glomerular filtrate each day. The natural glucoside phlorizin completely blocks glucose reabsorption. Oral SGLT2 inhibitors are rapidly absorbed into the blood stream, where theyremain in the circulation
openaire +2 more sources
SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
Frontiers in Cardiovascular Medicine, 2020 Three cardiovascular outcome trials of sodium glucose cotransporter 2 (SGLT2) inhibitors, including the EMPA-REG OUTCOME trial, CANVAS Program, and DECLARE TIMI 58 trial, revealed that SGLT2 inhibitors were superior to a matching placebo in reducing ...
Yasuhiro Maejima
doaj +1 more source
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
Cardiovascular Diabetology, 2022 Background There have been scarce data comparing cardiovascular outcomes between individual sodium-glucose cotransporter-2 (SGLT2) inhibitors. We aimed to compare the subsequent cardiovascular risk between individual SGLT2 inhibitors. Methods We analyzed
Yuta Suzuki +15 more
doaj +1 more source
International Journal of Cardiology: Heart & Vasculature, 2022 Background: Recent clinical trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors have beneficial effects on renal function in heart failure patients. This study confirmed the renoprotective effect of treatment with SGLT2 inhibitors in
Go Yokouchi +11 more
doaj +1 more source
Medicines, 2022 Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are still controversial.
Suriyon Uitrakul +4 more
doaj +1 more source
Development of SGLT1 and SGLT2 inhibitors [PDF]
Diabetologia, 2018 Sodium-glucose cotransporters SGLT1 (encoded by SGLT1, also known as SLC5A1) and SGLT2 (encoded by SGLT2, also known as SLC5A2) are important mediators of epithelial glucose transport. While SGLT1 accounts for most of the dietary glucose uptake in the intestine, SGLT2 is responsible for the majority of glucose reuptake in the tubular system of the ...
Timo Rieg, Volker Vallon
openaire +4 more sources
Diabetic ketoacidosis with SGLT2 inhibitors [PDF]
BMJ, 2020 ### What you need to know A 45 year old woman with type 2 diabetes complains of malaise, shortness of breath, and nausea for two days. She has been taking metformin and insulin. She was started on canagliflozin six weeks earlier to improve glycaemic control. Over the previous week she has halved the insulin dose. On examination, she is drowsy.
Giovanni, Musso +3 more
openaire +2 more sources
Frontiers in Cardiovascular Medicine, 2022 PurposeSodium-glucose cotransporter 2 (SGLT2) inhibitors have cardiorenal protective effects regardless of whether they are combined with type 2 diabetes mellitus, but their specific pharmacological mechanisms remain undetermined.Materials and MethodsWe ...
Anzhu Wang +13 more
doaj +1 more source
Therapeutic Advances in Chronic Disease, 2022 Objectives: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to reduce serum urate in patients with type 2 diabetes mellitus. To evaluate if this effect applies to both patients with and without diabetes, we conducted a systematic review
Alicia Swee Yan Yip +13 more
doaj +1 more source
SGLT2 Inhibitors and the Diabetic Kidney [PDF]
Diabetes Care, 2016 Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may ...
FIORETTO, PAOLA +4 more
openaire +3 more sources